Navigation Links
Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
Date:3/13/2008

re were no drug-related serious adverse events and no adverse events were considered to be definitely or probably related to study treatment. In the multiple ascending dose studies all possibly-related adverse events were mild in severity and resolved spontaneously.

"We're very encouraged with the results of the ex vivo response study that suggest a majority of Pompe patients may be treatable with our pharmacological chaperone AT2220," said John F. Crowley, President and CEO of Amicus Therapeutics. "Based on these data and the safety data from the Phase 1 studies, we look forward to commencing a Phase 2 clinical trial in Pompe patients the first half of this year."

As of November 2007, AT2220 is being developed in partnership with Shire Human Genetic Therapies (HGT), a business unit of Shire plc, which is focused on genetic diseases.

About Pompe Disease

Pompe disease affects an estimated 5,000-10,000 patients worldwide and is clinically heterogeneous in the age of onset, the extent of organ involvement, and the rate of progression. The early onset form of the disease is the most severe, progresses most rapidly, and is characterized by musculoskeletal, pulmonary, gastrointestinal, and cardiac symptoms that usually lead to death from cardio-respiratory failure between 1 and 2 years of age. The late onset form of the disease begins between childhood and adulthood and has a slower rate of progression that is characterized by musculoskeletal and pulmonary symptoms that usually lead to progressive weakness and respiratory insufficiency. A high majority of patients have the late onset form of the disease. The U.S. Food and Drug Administration's Office of Orphan Products Development has granted orphan drug designation for the active ingredient in AT2220 in the United States.

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the tre
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
2. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
3. Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease
4. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
5. Ception Therapeutics Initiates Phase II/III Clinical Trial for Its Lead Product Reslizumab in Eosinophilic Esophagitis (EE) in Children
6. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
7. InteKrin Therapeutics Announces Initiation of Phase 2b Study in Type 2 Diabetes with INT131
8. Oncology Drug Development Update - Molecular Profiling Redefines the Nature of Malignancy and Increases the Adoption of Targeted Therapeutics
9. TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds
10. Horizon Therapeutics Completes Enrollment in Phase 3 Trials for Lead Product Candidate HZT-501
11. Multiple Dose Clinical Trial of TorreyPines Therapeutics Tezampanel Demonstrates Compound is Safe and Well-Tolerated
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2008)... The following is being...: , , WHAT: World AIDS Day Audio Media Co...er 25, 2008 , 11:00 a.m. EST , Call-in numbe...https://cc.readytalk.com/r/1xe41i2yre8rs , ,...mber of people newly put on treatment worldwide, a...
(Date:11/20/2008)... LINE RESULTS OF FIRST PHASE III TRIAL SHOW SIGNIF...ROVEMENT IN DAILY FUNCTION, IN, ...Calif., and BRUSSELS, Belgium, Nov. 20 /PRNewswire...: JAZZ ) and UCB (Euronext Brussels: UCB),annou...rom the first of two,Phase III pivotal clinical t...
(Date:11/20/2008)... Nov. 20 Bionovo, Inc.,...nt results from the Phase 1B,clinical trial of th...east,cancer, BZL101, at the Society for Integrati...tlanta, Georgia. The Company,s oral presentation ...e presented as a part of the Best of the,SIO Sess...
(Date:11/20/2008)...PRNewswire/ -- Clinical data from a prospective,r...th Symposium shows DVT,treatment with the Trellis...lar, Inc. (Santa Clara, CA) successfully breaks up...tes. , This technique, called isolated phar...more quickly and safely than current catheter-dire...
Breaking Medicine Technology:Faith and Civil Society Leaders Call for Truth and Leadership in U.S. HIV Prevention Efforts 2Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia 2Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia 3Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia 4Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia 5Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia 6Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 2Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 3Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 4Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 5Trellis(R) Peripheral Infusion System Removes Blood Clots in Largest Reported Prospective Endovascular DVT (Deep Vein Thrombosis) Patient Series 2Trellis(R) Peripheral Infusion System Removes Blood Clots in Largest Reported Prospective Endovascular DVT (Deep Vein Thrombosis) Patient Series 3Scientists find elephant memories may hold key to survival 4417 1Scientists find elephant memories may hold key to survival 4417 2Scientists find elephant memories may hold key to survival 4417 3SCAN Health Plan Offers Seniors Five Tips to Prepare for Surgery 7067 1SCAN Health Plan Offers Seniors Five Tips to Prepare for Surgery 7067 2New Research Shows One in 200 People Born with DNA Mutation That Can Lead to Devastating Often Fatal Disease 2816 1New Research Shows One in 200 People Born with DNA Mutation That Can Lead to Devastating Often Fatal Disease 2816 2New Research Shows One in 200 People Born with DNA Mutation That Can Lead to Devastating Often Fatal Disease 2816 3Surviving the revolution easier than withstanding human use and abuse 4415 1Surviving the revolution easier than withstanding human use and abuse 4415 2Surviving the revolution easier than withstanding human use and abuse 4415 3
...ineRx Ltd.,(TASE:BLRX), Israel,s leading drug deve...e I trial of BL-1020, the first GABA,enhanced anti...schizophrenia. The trial demonstrated that the com...cal evidence of dopamine,blockade which is indicat... poster (Abstract 235 XX) at the 2007 American Psy...
...e of Cardiology,s,Board of Trustees has approved s...rising from his statements that resulted in the,br...go on the,COURAGE trial data presented at American...fic Session in March. ,The Board accepted the reco...Committee to issue a letter of censure to and proh...
Other Medicine Technology:BioLineRx Presents Data From Successful Phase I Trial for BL-1020,in Schizophrenia at American Psychiatric Association Conference 2BioLineRx Presents Data From Successful Phase I Trial for BL-1020,in Schizophrenia at American Psychiatric Association Conference 3BioLineRx Presents Data From Successful Phase I Trial for BL-1020,in Schizophrenia at American Psychiatric Association Conference 4
(Date:11/21/2008)...ire-USNewswire/ -- U.S. News & World Report an...QA) ranked BlueChoice(R) HealthPlan of South Carol...s(TM), published in U.S. News & World Report,s...ranking ranks the nation,s best health plans based... accreditation scores. NCQA and U.S. News & Wo...
(Date:11/21/2008)...ot cause genetic damage that can lead to disease ,...wo popular medications for treating attention-defi...etic damage linked to an increased risk for develo...e by researchers at Duke University Medical Center... previous one that reported biomarkers associated ...
(Date:11/21/2008)... -- For the second year in a row and the third ti...ldwide,s agency network won more creative awards t...ternational RX Club Show. , , Nine McCann ... 59 RX Club Awards of Excellence, including a Gold...ldwide agencies include Caudex Medical, echo Torre...
(Date:11/21/2008)...ore prevalent and smoking cessation less likely am...isorder (A.D.H.D.) In a study of smokers with att...ho exhibited elevated hyperactivity and impulsivit...rates after 8 weeks than those with inattention sy...s. The study, now available online in Nicotine a...
Breaking Medicine News(10 mins):Health News:BlueChoice HealthPlan Ranks in Top Third of America's Best Health Plans 2Health News:ADHD Medications Don't Pose Cancer Risk 2Health News:McCann Healthcare Worldwide Agencies Again Win Most Awards at RX Club Show 2008 2Health News:McCann Healthcare Worldwide Agencies Again Win Most Awards at RX Club Show 2008 3Health News:McCann Healthcare Worldwide Agencies Again Win Most Awards at RX Club Show 2008 4Health News:Ability to quit smoking may depend on ADHD symptoms, Columbia researchers find 2
...ird flu in Asia there comes news from China about ...lture of China has given the info that an outbreak...rm in Changqing District of Jinan City, capital of...ccurred. The incidence was reported when some cat...
...rest Mall, White Flint Mall or any other mall in A...s indelibly Indian//. This is Indian incense at it...andalwood, jasmine or the heady champa. "We are im... sticks) from India on a large scale," says Martha...
...itanandamayi plans to rehabilitate sex workers an...on center in various places//. Amritanandamayi i...f people, especially living in southern parts of I... in the same light as the next Mother Teresa of In...
...ment Advocacy center, Mary T. Zhanowicz, reports t...oviding mental support and treatment to people wit...entally support and provide care and help to menta...ally disturbed and there are increased chances of ...
Other Medicine News:Health News:Indian Incense Invades American Senses 2Health News:Rehabilitate Sex Workers - Mata Amritanandamayi 2
...e laboratory and a worldwide leader in innovative ...n extensive test menu of highly complex and unique... Owned by the University of Utah, ARUP Laboratorie...university teaching hospitals and children's hospi...
...e laboratory and a worldwide leader in innovative ...n extensive test menu of highly complex and unique... Owned by the University of Utah, ARUP Laboratorie...university teaching hospitals and children's hospi...
...sed in the ARED study, as well as the Lutein Antio... AMD disease progression in the study participants...ns efficacious amounts of nutrients suggested in p...as well as to support production of cellular (ATP)...
...ne and only vitamin and mineral formula proven eff... eye study (AREDS) 10-year trial. 4 tablets per da...sease Study (AREDS) by the National Eye Institute ...showed that a unique vitamin and mineral supplemen...
Medicine Products: